High pulse pressure linked to OAG

Article

High-tension open angle glaucoma (htOAG) is associated with high pulse pressure, increased carotid arterial stiffness and, in people treated for systemic hypertension, low diastolic perfusion pressure.

High-tension open angle glaucoma (htOAG) is associated with high pulse pressure, increased carotid arterial stiffness and, in people treated for systemic hypertension, low diastolic perfusion pressure, according to a report published in the June issue of Archives of Ophthalmology.

Caroline Hulsman and colleagues from The Netherlands Institute for Neuroscience conducted a study to investigate cross-sectional associations among blood pressures (BPs), arterial stiffness and open angle glaucoma (OAG). Participants were recruited from the population-based Rotterdam Study. Subjects were classified as either htOAG or normal tension OAG (ntOAG), according to an intraocular pressure (IOP) of greater than, or less than 21 mmHg. Pulse pressure was defined as the difference between systolic and diastolic BP, while diastolic perfusion pressure was defined as the difference between diastolic BP and IOP.

A total of 5,317 subjects were included in the study. In subjects with higher pulse pressure, the prevalence of htOAG was elevated. In those who were treated for systemic hypertension, low diastolic perfusion pressure (<50 mmHg) was inversely associated with ntOAG and positively associated with htOAG.

It was concluded that htOAG is particularly associated with high pulse pressure.

Recent Videos
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
John T. Thompson, MD, discusses his presentation at ASRS, Long-Term Results of Macular Hole Surgery With Long-Acting Gas Tamponade and Internal Limiting Membrane Peeling
ASRS 2024: Michael Singer, MD, shares 100-week results from the RESTORE trial
© 2024 MJH Life Sciences

All rights reserved.